Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody. The therapeutic candidate is being developed for the treatment of hidradenitis suppurativa and other inflammatory disorders. The company also released an updated investor presentation on its website. Avalo Therapeutics is a biotechnology company focused on developing therapies for inflammatory diseases.
